Evidence map›Paper›PMID 36302943›Full record

ArticleScientific reports2022

Long-term hospitalisations in survivors of paediatric solid tumours in France.

Daniel Bejarano-Quisoboni, Nathalie Pelletier-Fleury, Rodrigue S Allodji, Brice Fresneau, Majorie Boussac, Hélène Pacquement, François Doz, Delphine Berchery, Claire Pluchart, Piere-Yves Bondiau and 14 more

Abstract read
In one paragraph

Article in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Excess healthcare expenditure in adults treated for solid cancer in childhood: a cohort study in France.The European journal of health economics : HEPAC : health economics in prevention and care · 2024
    Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Daniel Bejarano-QuisoboniRadiation Epidemiology Team, CESP, Inserm U1018, Villejuif, France.
Nathalie Pelletier-FleuryPrimary care and Prevention Team, CESP, Inserm U1018, Villejuif, France.
Rodrigue S AllodjiRadiation Epidemiology Team, CESP, Inserm U1018, Villejuif, France.
Brice FresneauRadiation Epidemiology Team, CESP, Inserm U1018, Villejuif, France.
Majorie BoussacFrench National Health Insurance (CNAM), Paris, France.
Hélène PacquementSIREDO Center (Care, Research, Innovation in Pediatric, Adolescents and Young Adults Oncology), Institut Curie, Paris, France.
François DozSIREDO Center (Care, Research, Innovation in Pediatric, Adolescents and Young Adults Oncology), Institut Curie, Paris, France.
Delphine BercheryEpidemiology Unit, Claudius Regaud Institute, Toulouse, France.
Claire PluchartCentre Hospitalier Universitaire de Reims, Pediatric Oncology, Reims, France.
Piere-Yves BondiauRadiation Therapy, Antoine Lacassagne Cancer Center, Nice, France.
Julie NysRadiation Epidemiology Team, CESP, Inserm U1018, Villejuif, France.
Angela JacksonRadiation Epidemiology Team, CESP, Inserm U1018, Villejuif, France.
Charlotte Demoor-GoldschmidtRadiation Epidemiology Team, CESP, Inserm U1018, Villejuif, France.
Agnes DumasUniversité Paris Cité, Inserm, ECEVE, UMR 1123, Paris, France.
Cécile Thomas-TeinturierRadiation Epidemiology Team, CESP, Inserm U1018, Villejuif, France.
Boris SchwartzRadiation Epidemiology Team, CESP, Inserm U1018, Villejuif, France.
Neige JournyRadiation Epidemiology Team, CESP, Inserm U1018, Villejuif, France.
Carole RubinoRadiation Epidemiology Team, CESP, Inserm U1018, Villejuif, France.
Giao Vu-BezinRadiation Epidemiology Team, CESP, Inserm U1018, Villejuif, France.
Dominique Valteau-CouanetDepartment of Children and Adolescent Oncology, Gustave Roussy, Villejuif, France.
Chiraz El-FayechDepartment of Children and Adolescent Oncology, Gustave Roussy, Villejuif, France.
Christelle DufourDepartment of Children and Adolescent Oncology, Gustave Roussy, Villejuif, France.
Nadia HaddyRadiation Epidemiology Team, CESP, Inserm U1018, Villejuif, France.
Florent de VathaireRadiation Epidemiology Team, CESP, Inserm U1018, Villejuif, France. florent.devathaire@gustaveroussy.fr.

Funding

Agence Nationale de la Recherche ANR, HOPE-EPI projectFondation ARC pour la Recherche sur le Cancer POPHarC programFondation Gustave Roussy PSI IntervalLigue Contre le Cancer N°RAB20035LLAUniversité Paris-Saclay 9R_2019_PSU000101141_Upsud
6 · The paper itself

Abstract

The late effects of treatments for childhood cancers may lead to severe and multiple health conditions requiring hospitalisation. We aimed to estimate the hospitalisation rate among childhood cancer survivors (CCS) in France, to compare them with the general population and to investigate the associated factors. We matched total of 5439 5-year solid CCS diagnosed before the age of 21 between 1945 and 2000 by sex, birth year and region of residence to 386,073 individuals of the French general population. After linkage with the national hospital discharge database, we estimated the relative hospitalisation rate (RHR), the absolute excess risks (AERs) and the relative bed-day ratio (RBDR) during 2006-2018. We used generalised linear models to estimate associations between hospitalisation and survivor characteristics. Overall, the RHR was 2.49 (95% confidence interval [CI] 2.46-2.52) and the RBDR was 3.49 (95% CI 3.46-3.51). We found that neoplasm-related hospitalisations had the highest AER (105.8 per 1000 person-years), followed by genitourinary system diseases (34.4 per 1000 person-years) and cardiovascular diseases (19.2 per 1000 person-years). In adjusted analysis, CCS treated with chemotherapy (risk ratio [RR] 1.62, 95% CI 1.53-1.70), radiotherapy (RR 2.11, 95% CI 1.99-2.24) or both (RR 2.59, 95% CI 2.46-2.73) had a higher risk of hospitalisation than the ones who had not received any of these treatments. CCS treated during the past decades by chemotherapy and/or radiotherapy now had a higher hospitalisation risk for all main categories of diagnosis than the general population. Prevention strategies and medical surveillance programmes may promote a long-term decrease in the hospitalisation rate among CSS.

Indexed as

MultimorbidityNeoplasmsChildCross-Sectional StudiesHospitalizationHumansRisk FactorsSurvivors

Identifiers

PMID36302943
PMCPMC9613884

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.